Cargando…
Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies
Invasive aspergillosis is a life-threatening fungal infection predominately affecting immunocompromised individuals. The incidence of inpatient-treated aspergillosis cases in the US is estimated to be between 3.02 and 3.80 per 10,000 hospitalized patients. The estimated difference in hospital costs...
Autores principales: | Krueger, Kem P, Nelson, A Christie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169992/ https://www.ncbi.nlm.nih.gov/pubmed/21935305 |
Ejemplares similares
-
Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017) -
Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011) -
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011) -
Pharmacoeconomic considerations in the treatment of breast cancer
por: Pallis, Athanasios, et al.
Publicado: (2010) -
Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole
por: Ader, Florence, et al.
Publicado: (2009)